Cargando…

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BACKGROUND: We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk. METHODS: We used data for a retrospective cohort from a large U.S. health plan for Medicare benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Briasoulis, Alexandros, Gao, Yubo, Inampudi, Chakradhari, Alvarez, Paulino, Asleh, Rabea, Chrischilles, Elizabeth, Leira, Enrique C., Vaughan-Sarrazin, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998084/ https://www.ncbi.nlm.nih.gov/pubmed/32013886 http://dx.doi.org/10.1186/s12872-020-01340-4

Ejemplares similares

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
por: Inampudi, Chakradhari, et al.
Publicado: (2018)

The impact of insurance type on listing status and wait‐list mortality of patients with left ventricular assist devices as bridge to transplantation
por: Briasoulis, Alexandros, et al.
Publicado: (2020)

Approach to a patient with pulmonary hypertension
por: Inampudi, Chakradhari, et al.
Publicado: (2019)

Sex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation
por: Palamaner Subash Shantha, Ghanshyam, et al.
Publicado: (2017)

Potentially harmful drug prescription in elderly patients with heart failure with reduced ejection fraction
por: Alvarez, Paulino A., et al.
Publicado: (2020)

Trends, Perioperative Adverse Events, and Survival of Patients With Left Ventricular Assist Devices Undergoing Noncardiac Surgery
por: Mentias, Amgad, et al.
Publicado: (2020)

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
por: Asleh, Rabea, et al.
Publicado: (2022)

Outcomes after heart transplantation in patients with cardiac sarcoidosis
por: Asleh, Rabea, et al.
Publicado: (2022)

Racial and Sex Disparities in Anticoagulation After Electrical Cardioversion for Atrial Fibrillation and Flutter
por: Mentias, Amgad, et al.
Publicado: (2021)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

An Updated Pooled Analysis of Off-Label Under and Over-Dosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation
por: Shen, Nan-Nan, et al.
Publicado: (2023)

Patients and Their Physician’s Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant
por: Cannon, Christopher P., et al.
Publicado: (2023)

Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis
por: Mentias, Amgad, et al.
Publicado: (2018)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Trends in the rates of hospitalizations for acute stroke among patients over 90 years of age with atrial fibrillation in the United States: from 2005 to 2014
por: Shantha, Ghanshyam PS, et al.
Publicado: (2017)

978. Association of oral anticoagulation therapy with dabigatran and the incidence rate of Staphylococcus aureus bacteremia among patients with atrial fibrillation
por: Hasegawa, Shinya, et al.
Publicado: (2023)

Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
por: Wu, Xiaojuan, et al.
Publicado: (2021)

Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
por: Lee, Ji Yun, et al.
Publicado: (2021)

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy
por: Søgaard, Mette, et al.
Publicado: (2022)

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2022)

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation
por: Asleh, Rabea, et al.
Publicado: (2018)

Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2020)

State‐of‐the‐art machine learning improves predictive accuracy of 1‐year survival after heart transplantation
por: Kampaktsis, Polydoros N., et al.
Publicado: (2021)

Prevalence of oral anticoagulation in atrial fibrillation
por: Bartholomay, Eduardo, et al.
Publicado: (2014)

Anticoagulation in atrial fibrillation: the present and the future
por: Dweck, Marc R, et al.
Publicado: (2012)

Anticoagulation for atrial fibrillation in active cancer
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Off-label Use of Direct Oral Anticoagulants in Patients Receiving Surgical Mechanical and Bioprosthetic Heart Valves
por: Kalra, Ankur, et al.
Publicado: (2021)

Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice
por: Khalil, Fouad, et al.
Publicado: (2023)

Why Did All Patients with Atrial Fibrillation and High Risk of Stroke Not Receive Oral Anticoagulants? Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Szpotowicz, Anna, et al.
Publicado: (2021)

Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
por: Joosten, Linda P T, et al.
Publicado: (2023)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Association of Gender With Clinical Outcomes in a Contemporary Cohort of Patients With Atrial Fibrillation Receiving Oral Anticoagulants
por: Kim, Minjeong, et al.
Publicado: (2022)

Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral Anticoagulants
por: Lin, Kueiyu Joshua, et al.
Publicado: (2023)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
por: Santangeli, Pasquale, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nk9gr02hcd26icfipgv36p1pv8